ArticleMedicine2026
Prenatal phenotypes and pregnancy outcomes of fetuses with recurrent 16p13.11 microduplications.
Article in Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
16p13.11 microduplication is a frequently observed chromosomal abnormality in newborns. However, prenatal reports for this chromosome microscopic imbalance are rare in clinical practice. This study aimed to provide a systematic summary of prenatal phenotypes for this genomic disorder. Between April 2019 and May 2023, 10 pregnant women underwent amniocentesis due to fetal ultrasound abnormalities, advanced maternal age, or other prenatal diagnostic indications. After obtaining informed consent, chromosomal microarray analysis and G-banding were performed. Karyotype results were normal for all fetuses except in 2 cases (P2 and P5). Chromosomal microarray analysis detected 0.79 to 1.639 Mb duplications of 16p13.11 (chr16: 14806186-16444739, hg38) in all 10 cases, involving 4 morbid genes (NDE1, MYH11, ABCC1, and ABCC6) in common. Eight women (P1-P8) continued their pregnancies and delivered healthy infants at term, while the parents of cases 9 and 10 terminated their pregnancies. All neonates exhibited good health states without obvious abnormalities observed. The prenatal phenotypes of 16p13.11 duplications were primarily associated with abnormal soft markers, including increased nuchal translucency, ventriculomegaly, and enhanced intestinal echo. However, further evidence is needed to explore prenatal genotype-phenotype correlations. For prenatally diagnosed cases carrying 16p13.11 microduplications, long-term follow-up should be carried out to acquire their postnatal health conditions and growth details.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.